|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CASE 1 | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | |
| Tumor Description | | | | | **Grade** | | | | | | **Tumor Size** | | | | | | | |
| Primary Site | |  | | | **Clinical** | | | |  | | **Clinical** | | | |  | | | |
| Laterality | |  | | | **Pathological** | | | |  | | **Pathological** | | | |  | | | |
| Histology | |  | | | **Post Therapy (yc)** | | | |  | | **Summary** | | | |  | | | |
| Behavior | |  | | | **Post Therapy (yp)** | | | |  | |  | | | | | | | |
| AJCC Staging Items | | | | | | | | | | | | | | | | | | | |
| Clinical T |  | | **Pathological T** | | | |  | **Post-therapy cT** | | | |  | | **Post-therapy pT** | | |  | | |
| cT Suffix |  | | **pT Suffix** | | | |  | **ypT Suffix** | | | |  | | **ypT Suffix** | | |  | | |
| Clinical N |  | | **Pathological N** | | | |  | **Post-therapy cN** | | | |  | | **Post-therapy pN** | | |  | | |
| cN Suffix |  | | **pN Suffix** | | | |  | **ypN Suffix** | | | |  | | **ypN Suffix** | | |  | | |
| Clinical M |  | | **Pathological M** | | | |  | **Post-therapy M** | | | |  | | **Post-therapy M** | | |  | | |
| Stage Group |  | | **Stage Group** | | | |  | **Stage Group** | | | |  | | **Stage Group** | | |  | | |
| SS2018/EOD | | | | | | | | | | | | | | | | | |
| Summary Stage 2018 | | | |  | |  | | | | | | | | | | | |
| Extent of Disease | | | | | | | | | | | | | | | | | |
| EOD Primary Tumor | | | |  | | **EOD Regional Nodes** | | | |  | | | **EOD Mets** | | |  | |

|  |  |
| --- | --- |
| Regional Nodes Positive |  |
| Regional Nodes Examined |  |
| SSDI | | **LN H/N VI-VII** | |  | **LN H/N Other** | |  |
| Schema Discriminator 1 |  | **ENE Pathological** | |  | **LN H/N levels I-III** | |  |
| ENE Clinical |  | **LN Size of Mets** | |  | **LN H/N levels IV-V** | |  |
| Treatment | | | | | | | |
| Surgery Codes | | | | **Systemic Therapy Codes** | | | |
| Diagnostic Staging Procedure | | |  | **Chemotherapy** | |  | |
| Surgical Procedure of Primary Site | | |  | **Hormone Therapy** | |  | |
| Scope of RLN Node Surgery | | |  | **Immunotherapy** | |  | |
| Radiation | | | | | | | |
| Phase | | | 1 2 3 |  | | 1 2 3 | |
| Primary Treatment Volume | | |  | **Dose Per fraction** | |  | |
| Draining LN | | |  | **Fractions** | |  | |
| Modality | | |  | **Total Dose** | |  | |
| EB Planning Technique | | |  |  | |  | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CASE 2 | | | | | | | | | | | | | | | | | | |
| Tumor Description | | | | | **Grade** | | | | | | **Tumor Size** | | | | | | | |
| Primary Site | |  | | | **Clinical** | | | |  | | **Clinical** | | | |  | | | |
| Laterality | |  | | | **Pathological** | | | |  | | **Pathological** | | | |  | | | |
| Histology | |  | | | **Post Therapy (yc)** | | | |  | | **Summary** | | | |  | | | |
| Behavior | |  | | | **Post Therapy (yp)** | | | |  | |  | | | | | | | |
| AJCC Staging Items | | | | | | | | | | | | | | | | | | | |
| Clinical T |  | | **Pathological T** | | | |  | **Post-therapy cT** | | | |  | | **Post-therapy pT** | | | |  | |
| cT Suffix |  | | **pT Suffix** | | | |  | **ypT Suffix** | | | |  | | **ypT Suffix** | | | |  | |
| Clinical N |  | | **Pathological N** | | | |  | **Post-therapy cN** | | | |  | | **Post-therapy pN** | | | |  | |
| cN Suffix |  | | **pN Suffix** | | | |  | **ypN Suffix** | | | |  | | **ypN Suffix** | | | |  | |
| Clinical M |  | | **Pathological M** | | | |  | **Post-therapy M** | | | |  | | **Post-therapy M** | | | |  | |
| Stage Group |  | | **Stage Group** | | | |  | **Stage Group** | | | |  | | **Stage Group** | | | |  | |
| SS2018/EOD | | | | | | | | | | | | | | | | |
| Summary Stage 2018 | | | |  | |  | | | | | | | | | | |
| Extent of Disease | | | | | | | | | | | | | | | | |
| EOD Primary Tumor | | | |  | | **EOD Regional Nodes** | | | |  | | | **EOD Mets** | | |  |

|  |  |  |
| --- | --- | --- |
| Regional Nodes Positive | |  |
| Regional Nodes Examined | |  |
| SSDIs | | | | | | |
| Schema Discriminator 2 | |  | **ENE Pathological** | | |  |
| ENE Clinical | |  | **LN Size of Mets** | | |  |
| Treatment | | | | | | | |
| Surgery Codes | | | | **Systemic Therapy Codes** | | | |
| Diagnostic Staging Procedure |  | | | **Chemotherapy** |  | | |
| Surgical Procedure of Primary Site |  | | | **Hormone Therapy** |  | | |
| Scope of Regional Lymph Node Surgery |  | | | **Immunotherapy** |  | | |
| Radiation | | | | | | | |
| Phase | 1 2 3 | | |  | 1 2 3 | | |
| Primary Treatment Volume |  | | | **Dose per FX** |  | | |
| Draining LN |  | | | **Fractions** |  | | |
| Modality |  | | | **Total Dose** |  | | |
| EB Planning technique |  | | |  |  | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CASE 3 | | | | | | | | | | | | | | | | | | |
| Tumor Description | | | | | **Grade** | | | | | | **Tumor Size** | | | | | | | |
| Primary Site | |  | | | **Clinical** | | | |  | | **Clinical** | | | |  | | | |
| Laterality | |  | | | **Pathological** | | | |  | | **Pathological** | | | |  | | | |
| Histology | |  | | | **Post Therapy (yc)** | | | |  | | **Summary** | | | |  | | | |
| Behavior | |  | | | **Post Therapy (yp)** | | | |  | |  | | | | | | | |
| AJCC Staging Items | | | | | | | | | | | | | | | | | | | |
| Clinical T |  | | **Pathological T** | | | |  | **Post-therapy cT** | | | |  | | **Post-therapy pT** | | | |  | |
| cT Suffix |  | | **pT Suffix** | | | |  | **ypT Suffix** | | | |  | | **ypT Suffix** | | | |  | |
| Clinical N |  | | **Pathological N** | | | |  | **Post-therapy cN** | | | |  | | **Post-therapy pN** | | | |  | |
| cN Suffix |  | | **pN Suffix** | | | |  | **ypN Suffix** | | | |  | | **ypN Suffix** | | | |  | |
| Clinical M |  | | **Pathological M** | | | |  | **Post-therapy M** | | | |  | | **Post-therapy M** | | | |  | |
| Stage Group |  | | **Stage Group** | | | |  | **Stage Group** | | | |  | | **Stage Group** | | | |  | |
| SS2018/EOD | | | | | | | | | | | | | | | | |
| Summary Stage 2018 | | | |  | |  | | | | | | | | | | |
| Extent of Disease | | | | | | | | | | | | | | | | |
| EOD Primary Tumor | | | |  | | **EOD Regional Nodes** | | | |  | | | **EOD Mets** | | |  |

|  |  |
| --- | --- |
| Regional Nodes Positive |  |
| Regional Nodes Examined |  |
| SSDIs | | | | | |
| Schema Discriminator 2 |  | **ENE Pathological** | | |  |
| ENE Clinical |  | **LN Size of Mets** | | |  |
| Treatment | | | | | | |
| Surgery Codes | | | **Systemic Therapy Codes** | | | |
| Diagnostic Staging Procedure |  | | **Chemotherapy** |  | | |
| Surgical Procedure of Primary Site |  | | **Hormone Therapy** |  | | |
| Scope of Regional Lymph Node Surgery |  | | **Immunotherapy** |  | | |
| Radiation | | | | | | |
| Phase | 1 2 3 | |  | 1 2 3 | | |
| Primary Treatment Volume |  | | **Dose per FX** |  | | |
| Draining LN |  | | **Fractions** |  | | |
| Modality |  | | **Total Dose** |  | | |
| EB Planning technique |  | |  |  | | |